Podcasts about entrepreneurial learning cfel

Dr David Cleevely knows a thing or two about building businesses. A serial entrepreneur and investor, he has worked at the heart of the Cambridge Cluster on numerous ventures including telecoms consultancy Analysys, web based antibody company Abcam (ABC.L); and G femto base station company, 3WayNetworks. Abcam, which he co-founded in 1998 and was Chairman of until 2009, currently has a $1.5bn valuation - not bad for a company that starting selling antibodies door-to-door on a bike! David is the guest speaker at the launch session of the 2014/15 Enterprise Tuesday series on 4 November at the University of Cambridge's Department of Engineering. He will focus on telling the Abcam story but also look at other billion dollar companies that have come out of Cambridge. It's a good opportunity for those working in or contemplating a future in entrepreneurship to learn more about growing successful businesses. Read more about David Cleevely » http://www.cfel.jbs.cam.ac.uk/programmes/enterprisetuesday/programme/speakers/cleevelyd.html Find out more about Abcam » http://www.abcam.com/ Without passion you cannot succeed! Listen to this podcast with Dr David Cleevely » http://www.sms.cam.ac.uk/media/1122496 Recognising opportunities … Watch video of Dr David Cleevely and Dr Andy Richards here » http://www.sms.cam.ac.uk/media/726139 Enterprise Tuesday is a series of FREE evening lectures and networking sessions delivered by the Centre for Entrepreneurial Learning (CfEL) which take place from November to the end of February in Cambridge. The programme aims to introduce participants to the world of business, as well as to encourage and inspire individuals to pursue their entrepreneurial ambition. It is the most popular non-assessed programme within the University and the model has been adopted by numerous other academic institutions as well as corporations. Enterprise Tuesday is open to all University of Cambridge staff and students, members of other universities and the local business community. The series is particularly relevant for postgraduate students considering future career paths, those exploring entrepreneurial opportunities and looking to build high quality networks with experts and practitioners. Find out more about Enterprise Tuesday at http://www.cfel.jbs.cam.ac.uk/programmes/enterprisetuesday/index.html

Dr David Cleevely knows a thing or two about building businesses. A serial entrepreneur and investor, he has worked at the heart of the Cambridge Cluster on numerous ventures including telecoms consultancy Analysys, web based antibody company Abcam (ABC.L); and G femto base station company, 3WayNetworks. Abcam, which he co-founded in 1998 and was Chairman of until 2009, currently has a $1.5bn valuation - not bad for a company that starting selling antibodies door-to-door on a bike! David is the guest speaker at the launch session of the 2014/15 Enterprise Tuesday series on 4 November at the University of Cambridge's Department of Engineering. He will focus on telling the Abcam story but also look at other billion dollar companies that have come out of Cambridge. It's a good opportunity for those working in or contemplating a future in entrepreneurship to learn more about growing successful businesses. Read more about David Cleevely » http://www.cfel.jbs.cam.ac.uk/programmes/enterprisetuesday/programme/speakers/cleevelyd.html Find out more about Abcam » http://www.abcam.com/ Without passion you cannot succeed! Listen to this podcast with Dr David Cleevely » http://www.sms.cam.ac.uk/media/1122496 Recognising opportunities … Watch video of Dr David Cleevely and Dr Andy Richards here » http://www.sms.cam.ac.uk/media/726139 Enterprise Tuesday is a series of FREE evening lectures and networking sessions delivered by the Centre for Entrepreneurial Learning (CfEL) which take place from November to the end of February in Cambridge. The programme aims to introduce participants to the world of business, as well as to encourage and inspire individuals to pursue their entrepreneurial ambition. It is the most popular non-assessed programme within the University and the model has been adopted by numerous other academic institutions as well as corporations. Enterprise Tuesday is open to all University of Cambridge staff and students, members of other universities and the local business community. The series is particularly relevant for postgraduate students considering future career paths, those exploring entrepreneurial opportunities and looking to build high quality networks with experts and practitioners. Find out more about Enterprise Tuesday at http://www.cfel.jbs.cam.ac.uk/programmes/enterprisetuesday/index.html

Dr Shima Barakat, Research & Teaching Fellow in Enterprise at the Centre for Entrepreneurial Learning (CfEL), Cambridge Judge Business School, features in a Cambridge book The Meaning of Success and on the accompanying website at http://www.cam.ac.uk/women-at-cambridge, speaking about her career and philosophy of success. The book brings together the stories of women from across the University of Cambridge and examines what success means to them as they share the individual life journeys that have led them to Cambridge. In interviews with twenty-six women connected with the University, along with contributions from a hundred more, it makes a compelling case for a more inclusive definition of success. The Vice-Chancellor Professor Sir Leszek Borysiewicz said: “By exploring these inspirational stories, this book reminds the reader that talent and excellence can be found across the University and in every walk of life. It provides an opportunity to reflect on how success is recognised and rewarded, giving us scope to redefine and extend the qualities and attributes we associate with being successful.” In this podcast interview, Shima talks about her own experiences as a women engineer and academic as well as her research specifically into women in entrepreneurship. She cites the importance of encouraging women to be more enterprising and to overcome traditional challenges as a result of gender dynamics. Shima has direct experience as a woman engineer of workplace chauvinism and prejudice but has always sought to challenge and change attitudes and practices. As a young engineer working on the construction of the Cairo Metro with 400 men, she was given a key to a toilet that was three streets away. So, she commandeered the onsite men’s toilet when needed putting up a sign stating ‘occupied for feminine use’. In her academic work, she has found evidence showing that a founding team or company board with a better gender balance tends to use 30% less resources, return 12% more and fair better in times of adversity. There’s also evidence of women doing things differently and that this diversity can be beneficial to the organization. And yet there are very few women on company boards and a shortage of women in senior positions in academia. Shima advocates a review of structural and organizational issues that break down stereotypes and forge new pathways for success both in companies and academia.

Dr Shima Barakat, Research & Teaching Fellow in Enterprise at the Centre for Entrepreneurial Learning (CfEL), Cambridge Judge Business School, features in a Cambridge book The Meaning of Success and on the accompanying website at http://www.cam.ac.uk/women-at-cambridge, speaking about her career and philosophy of success. The book brings together the stories of women from across the University of Cambridge and examines what success means to them as they share the individual life journeys that have led them to Cambridge. In interviews with twenty-six women connected with the University, along with contributions from a hundred more, it makes a compelling case for a more inclusive definition of success. The Vice-Chancellor Professor Sir Leszek Borysiewicz said: “By exploring these inspirational stories, this book reminds the reader that talent and excellence can be found across the University and in every walk of life. It provides an opportunity to reflect on how success is recognised and rewarded, giving us scope to redefine and extend the qualities and attributes we associate with being successful.” In this podcast interview, Shima talks about her own experiences as a women engineer and academic as well as her research specifically into women in entrepreneurship. She cites the importance of encouraging women to be more enterprising and to overcome traditional challenges as a result of gender dynamics. Shima has direct experience as a woman engineer of workplace chauvinism and prejudice but has always sought to challenge and change attitudes and practices. As a young engineer working on the construction of the Cairo Metro with 400 men, she was given a key to a toilet that was three streets away. So, she commandeered the onsite men’s toilet when needed putting up a sign stating ‘occupied for feminine use’. In her academic work, she has found evidence showing that a founding team or company board with a better gender balance tends to use 30% less resources, return 12% more and fair better in times of adversity. There’s also evidence of women doing things differently and that this diversity can be beneficial to the organization. And yet there are very few women on company boards and a shortage of women in senior positions in academia. Shima advocates a review of structural and organizational issues that break down stereotypes and forge new pathways for success both in companies and academia.

The Centre for Entrepreneurial Learning (CfEL) talked to Dr Helen Lee, Director of Research, Department of Haematology, University of Cambridge and Founder Diagnostics for the Real World about her very considerable experiences in diagnostics, founding companies, and the need to develop usable products for people in the developing world. Helen received her PhD from Cornell University and MSc from Oxford University. After post-doctoral training at Churchill Hospital in Oxford, the University of Geneva and St Louis Hospital in Paris, she began her career in diagnostics at the Centre National de Transfusion Sanguine in Paris where she was responsible for developing monoclonal blood typing reagents, the first widely used liquid blood typing reagents in Paris. Another major accomplishment of her group was one of the first monoclonal antibody based assays for hepatitis B surface antigen, which was subsequently licensed to the Pasteur Institute as the MONLISA HBsAg assay and is still on the market today. She then joined Abbott Laboratories to be responsible for Research & Development, and was promoted to General Manager of the Probe Diagnostics Business Unit where she managed over 100 people and an annual budget of >$20 million. She was also responsible for production of instruments as well as chemistry, marketing, quality and regulatory affairs of the product line. After leaving Abbott she founded a biotech company, Sentinel Biosciences Inc. in Palo Alto, CA, developing technologies for virus discovery. The company was successfully sold to one of the world's largest pharmaceutical companies. In 1996, she left industry for the University of Cambridge in order to focus on the development of technology and diagnostic assay for resource-poor settings. To commercialise the technologies developed at Cambridge, she founded the spin off company, Diagnostics for the Real World Ltd (DRW), in 2002. Awards: Dr Lee chaired the Diagnostic Steering Committee at the World Health Organization (WHO). She is the recipient of the 2005 Lord Lloyd Kilgerran Award, the 2006 British Female Inventor in Industry Award, the 2006 European Women of Achievement Award and the 2007 Asian Women of Achievement Award (presentation as pdf). The products and technologies developed by DDU scientists received the Medical Futures Innovation Award (UK) for its innovative sample collection device and more recently, the 2007 Tech Museum Innovation Award (US) for innovation in the Health Category, in recognition of the Signal Amplification technology, which greatly improves the sensitivity of rapid test for the detection of infectious diseases (see video interview) (hear audio interview). The unit has filed 12 families of patent applications, with 20 granted or allowed national patents, detailing inventions that improve the performance of rapid diagnostic test.

The Centre for Entrepreneurial Learning (CfEL) talked to Dr Helen Lee, Director of Research, Department of Haematology, University of Cambridge and Founder Diagnostics for the Real World about her very considerable experiences in diagnostics, founding companies, and the need to develop usable products for people in the developing world. Helen received her PhD from Cornell University and MSc from Oxford University. After post-doctoral training at Churchill Hospital in Oxford, the University of Geneva and St Louis Hospital in Paris, she began her career in diagnostics at the Centre National de Transfusion Sanguine in Paris where she was responsible for developing monoclonal blood typing reagents, the first widely used liquid blood typing reagents in Paris. Another major accomplishment of her group was one of the first monoclonal antibody based assays for hepatitis B surface antigen, which was subsequently licensed to the Pasteur Institute as the MONLISA HBsAg assay and is still on the market today. She then joined Abbott Laboratories to be responsible for Research & Development, and was promoted to General Manager of the Probe Diagnostics Business Unit where she managed over 100 people and an annual budget of >$20 million. She was also responsible for production of instruments as well as chemistry, marketing, quality and regulatory affairs of the product line. After leaving Abbott she founded a biotech company, Sentinel Biosciences Inc. in Palo Alto, CA, developing technologies for virus discovery. The company was successfully sold to one of the world's largest pharmaceutical companies. In 1996, she left industry for the University of Cambridge in order to focus on the development of technology and diagnostic assay for resource-poor settings. To commercialise the technologies developed at Cambridge, she founded the spin off company, Diagnostics for the Real World Ltd (DRW), in 2002. Awards: Dr Lee chaired the Diagnostic Steering Committee at the World Health Organization (WHO). She is the recipient of the 2005 Lord Lloyd Kilgerran Award, the 2006 British Female Inventor in Industry Award, the 2006 European Women of Achievement Award and the 2007 Asian Women of Achievement Award (presentation as pdf). The products and technologies developed by DDU scientists received the Medical Futures Innovation Award (UK) for its innovative sample collection device and more recently, the 2007 Tech Museum Innovation Award (US) for innovation in the Health Category, in recognition of the Signal Amplification technology, which greatly improves the sensitivity of rapid test for the detection of infectious diseases (see video interview) (hear audio interview). The unit has filed 12 families of patent applications, with 20 granted or allowed national patents, detailing inventions that improve the performance of rapid diagnostic test.

The Centre for Entrepreneurial Learning (CfEL) talked to Mary Anne Cordeiro, Director of Albion Income and Growth Venture Capital Trust plc and Director of Science to Business about her experiences of helping early stage technologies with product development and how those within the bio sector need to think outside the box. Mary Anne is an Oxford University graduate who had a fifteen year career in the City with Goldman Sachs, Bankers Trust and Paribas giving her extensive expertise in all aspects of corporate finance. Since 1998, she has been working on the commercialisation of innovation and has helped develop strategies to bring new products and services to market as well as to finance growth. She is motivated by what she perceives as a big gap between getting scientists ‘off the bench and on the road’ and then evolving start-ups into sustainable businesses. Most scientists see the problem as being about improving the technology rather than spotting the market opportunity and meeting the market need. Mary Anne realised she needed to get involved at an early stage in order to advise and enable inventors and start-ups to create compelling business propositions that savvy business angels would invest in. During the interview, she cites an example of how thinking outside the box helped a company, Myoton, accelerate product development. The original technology product offered was such that sales were made only to scientists but this changed in 2010 when the company was awarded grant-funding by the EU Space Agency. It enabled development of the technology for use in micro-gravity and required complete redevelopment of the mechanics and software to cope with the environment in space. The result was a more versatile and user-friendly product which can be used in most healthcare settings. It has transformed the company into a viable, sustainable business.

The Centre for Entrepreneurial Learning (CfEL) talked to Mary Anne Cordeiro, Director of Albion Income and Growth Venture Capital Trust plc and Director of Science to Business about her experiences of helping early stage technologies with product development and how those within the bio sector need to think outside the box. Mary Anne is an Oxford University graduate who had a fifteen year career in the City with Goldman Sachs, Bankers Trust and Paribas giving her extensive expertise in all aspects of corporate finance. Since 1998, she has been working on the commercialisation of innovation and has helped develop strategies to bring new products and services to market as well as to finance growth. She is motivated by what she perceives as a big gap between getting scientists ‘off the bench and on the road’ and then evolving start-ups into sustainable businesses. Most scientists see the problem as being about improving the technology rather than spotting the market opportunity and meeting the market need. Mary Anne realised she needed to get involved at an early stage in order to advise and enable inventors and start-ups to create compelling business propositions that savvy business angels would invest in. During the interview, she cites an example of how thinking outside the box helped a company, Myoton, accelerate product development. The original technology product offered was such that sales were made only to scientists but this changed in 2010 when the company was awarded grant-funding by the EU Space Agency. It enabled development of the technology for use in micro-gravity and required complete redevelopment of the mechanics and software to cope with the environment in space. The result was a more versatile and user-friendly product which can be used in most healthcare settings. It has transformed the company into a viable, sustainable business.

The Centre for Entrepreneurial Learning (CfEL) talked to Dr Andy Richards, serial biotechnology entrepreneur and business angel, about determining and defining effective business models in the life sciences sector. He talks about the particular challenges of the sector where high market value and mass market need is contrasted by tight regulatory process and high cost to market. This combined with the high risk of failure means it is a challenge to pitch to investors. Dr Richards encourages inventors and innovators to protect intellectual property through patents but also to think carefully about the timing of such patents as this is equally important. He also emphasises the importance of avoiding formulaic, text book responses to planning and the need to evolve your business model as you move up the value chain. In his view, success is not so much measured by how much money you make but how you have helped patients or end users through innovations in healthcare.

The Centre for Entrepreneurial Learning (CfEL) talked to Dr Andy Richards, serial biotechnology entrepreneur and business angel, about determining and defining effective business models in the life sciences sector. He talks about the particular challenges of the sector where high market value and mass market need is contrasted by tight regulatory process and high cost to market. This combined with the high risk of failure means it is a challenge to pitch to investors. Dr Richards encourages inventors and innovators to protect intellectual property through patents but also to think carefully about the timing of such patents as this is equally important. He also emphasises the importance of avoiding formulaic, text book responses to planning and the need to evolve your business model as you move up the value chain. In his view, success is not so much measured by how much money you make but how you have helped patients or end users through innovations in healthcare.

Mr Julian Hitchcock, Counsel at law firm Lawford Davies Denoon The Centre for Entrepreneurial Learning (CfEL) talked to Julian Hitchcock, Counsel at law firm Lawford Davies Denoon (www.lawforddaviesdenoon.com), about intellectual property rights issues for those looking to extract the maximum value from innovations in the complex Life Sciences sector. He emphasises the importance of doing due diligence to fully understand the patent landscape and the regulatory route to market before talking to potential investors. There are some recommended sites for patent searches which are provided in the links below. In particular, Julian advises inventors that the core assets of a Life Sciences company are the intellectual property. The idea of treating your lab as a castle and keeping your inventions and the means of exploiting markets and commercial value under lock and key is highly important. Recommended sites for patent searching: • Espacenet - http://worldwide.espacenet.com/ • Espacenet assistant (learn how to search) - http://www.european-patent-office.org/wbt/espacenet/assistant.php Other useful sites: • www.ipo.gov.uk • www.bl.uk/collections/patents

Mr Julian Hitchcock, Counsel at law firm Lawford Davies Denoon The Centre for Entrepreneurial Learning (CfEL) talked to Julian Hitchcock, Counsel at law firm Lawford Davies Denoon (www.lawforddaviesdenoon.com), about intellectual property rights issues for those looking to extract the maximum value from innovations in the complex Life Sciences sector. He emphasises the importance of doing due diligence to fully understand the patent landscape and the regulatory route to market before talking to potential investors. There are some recommended sites for patent searches which are provided in the links below. In particular, Julian advises inventors that the core assets of a Life Sciences company are the intellectual property. The idea of treating your lab as a castle and keeping your inventions and the means of exploiting markets and commercial value under lock and key is highly important. Recommended sites for patent searching: • Espacenet - http://worldwide.espacenet.com/ • Espacenet assistant (learn how to search) - http://www.european-patent-office.org/wbt/espacenet/assistant.php Other useful sites: • www.ipo.gov.uk • www.bl.uk/collections/patents

The Centre for Entrepreneurial Learning (CfEL) interviewed Lewis Liu, Co-founder and President at CamGaN, and Andrew Lynn, entrepreneur and former CEO of OrthoMimetics and CamGaN, about their involvement in the success of University spin-out CamGaN which was formed in October 2010 to commercialise ground-breaking research in the field of gallium nitride based light-emitting diodes (LEDs) at the University of Cambridge. These two are graduates of the University of Cambridge’s Department of Materials Science and attended CfEL’s Ignite programme. They talk about the challenges of bringing this University-based technology to market. For further information on CamGaN read their press release here (8 Feb 2012) » http://www.enterprise.cam.ac.uk/news/2012/2/cambridge-spin-out-camgan-acquired-plessey/

The Centre for Entrepreneurial Learning (CfEL) interviewed Lewis Liu, Co-founder and President at CamGaN, and Andrew Lynn, entrepreneur and former CEO of OrthoMimetics and CamGaN, about their involvement in the success of University spin-out CamGaN which was formed in October 2010 to commercialise ground-breaking research in the field of gallium nitride based light-emitting diodes (LEDs) at the University of Cambridge. These two are graduates of the University of Cambridge’s Department of Materials Science and attended CfEL’s Ignite programme. They talk about the challenges of bringing this University-based technology to market. For further information on CamGaN read their press release here (8 Feb 2012) » http://www.enterprise.cam.ac.uk/news/2012/2/cambridge-spin-out-camgan-acquired-plessey/